View this email in your browser

Welcome back to the Infectious Disease Curator!

Isn't it great to end the week on a truly positive note? If you haven't already heard the great news, the World Health Organization has approved the first ever malaria vaccine!

Just 48 hours ago, the WHO announced it is “recommending widespread use of the RTS,S/AS01 (RTS,S) malaria vaccine among children in sub-Saharan Africa and in other regions with moderate to high P. falciparum malaria transmission."

Targeting the most deadly malaria parasite, the vaccine (used on top of existing efforts) could save tens of thousands of lives per year. The WHO has recommended that RTS,S/AS01 should be administered in a four-dose regimen in children from five months of age.

Matshidiso Moeti, WHO Regional Director for Africa, noted, “We have long hoped for an effective malaria vaccine and now, for the first time ever, we have such a vaccine recommended for widespread use. Today’s recommendation offers a glimmer of hope for the continent which shoulders the heaviest burden of the disease, and we expect many more African children to be protected from malaria and grow into healthy adults."

Where to go from here? The global health community will need to make funding decisions while countries decide whether to adopt RTS,S/AS01 into their national malaria control strategies.

Until next week,

Liv Gaskill, The Curator


Essential Reading

Big breakthrough. Merck has announced that its investigational oral antiviral treatment, molnupiravir, significantly reduces risk of hospitalization or death by 50 percent in at-risk, non-hospitalized adult patients with mild to moderate COVID-19. The company plans to apply for FDA Emergency Use Authorization as soon as possible.

Half-year half-life. A study into the Pfizer-BioNTech vaccine has found that two doses are 90 percent effective against hospitalization for at least six months, even with the introduction of the delta variant. Vaccine effectiveness significantly declines after six months, but the authors note this is likely due to waning immunity, rather than delta escape.

Unexpected findings. An 11-year longitudinal study of 4,189 Nicaraguan children has found that antibody responses from natural infection with Dengue and Zika virus remain unexpectedly stable over time. After secondary infection, these cross-reactive antibodies waned slowly. The results could change understanding of immunity to Dengue and Zika virus and inform future studies of vaccine efficacy.

Plague paranoia? Dynavax Technologies Corporation and the US Department of Defense (DoD) have announced a partnership to develop a recombinant plague vaccine adjuvanted with CpG 1018. With the looming threat of bioterrorism, the DoD wants to ensure US soldiers can fight and win any war in the chemical, biological, radiological, and nuclear (CBRN) battlespace.

Maintain consistency with reliable media manufacturing solutions

Achieving consistency when scaling up your proprietary media formulation is essential. Join forces with the trusted pioneer of scalable bioprocessing solutions for reliable cGMP media manufacturing.

Find out more >
Worth Your Time...

Infectious Disease

War in the gut. Study investigates how Vibrio cholerae interacts with bacteria of human gut microbiota; finds significant subset of gut bacteria can resist T6SS-mediated attacks by V. cholerae [LINK]

Not impossible. Surface-enhanced Raman spectroscopy could be key to fast and accurate clinical test for Clostridium difficile infection in hospitals [LINK]

New day, new virus. Novel infectious virus, named Yezo virus, identified by scientists in Japan is transmitted by tick bites and causes acute febrile illness in infected patients [LINK]

Candidate zoonoses. New study suggests machine learning using viral genomes may help to predict likelihood of zoonotic viruses infecting humans [LINK]

Incompatible insects. Release of Aedes aegypti males infected with Wolbachia from A. albopictus found to strongly suppress populations of wild-type (no Wolbachia) and wMel-Wolbachia-carrying A. aegypti  [LINK]

Delaying dengue. Researchers demonstrate highly potent dengue virus inhibitor (JNJ-A07) is effective in mouse models of infection; delaying start of treatment until peak viremia led to rapid and significant reduction in viral load [LINK]


Immune signatures. Research uncovers immunological traits associated with lung sequelae in COVID-19 patients; dysregulated respiratory CD8+ T cell function linked to lung health following infection [LINK]

Lineage learnings. SARS-CoV-2 lineage B.1.620 shares similarities with several variants of concern and could be resistant to currently available neutralizing antibodies [LINK]

Stool samples. Recommended approach to fecal detection of SARS-CoV-2 could lead to standardized testing; recommendations include establishing limit of bank with every batch of experiments and reporting quantified viral RNA load in terms of copies per gram of stool [LINK]

Tagged and pooled. Diagnostic tool, ApharSeq, could allow for concurrent sequencing and detection of COVID-19 variants [LINK]

Purification nation. Protocol used to develop spike variant, HexPro, can be applied to purification of other spike proteins in under seven days [LINK]

Pediatric profiling. Antibody profiling in in MIS-C and pediatric COVID-19 patients reveals that higher antibody avidity to NSP2 and SARS-CoV-2 prefusion spike protein is associated with decreased clinical disease severity [LINK]
Finding The Infectious Disease Curator useful? Share it...
Post Post
Tweet Tweet
Share Share
Email Email
Subscribe to The Infectious Disease Curator
If you're not subscribed to The Infectious Disease Curator:  join us

Got infectious disease-related science news? Share it with Michael - Email // Twitter // LinkedIn

Update preferences // Unsubscribe
Published by
Texere Publishing
Booths Park
Knutsford, WA16 8GS
United Kingdom

Add us to your address book

Copyright © 2021 Texere Publishing, All rights reserved.